5-甲基恶唑-4-甲酸甲酯 | 41172-57-0

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-甲基恶唑-4-甲酸甲酯
• 中文别名: 5-甲基噁唑-4-羧酸甲酯；5-甲基恶唑-4-羧酸甲酯
• 英文名称: methyl 5-methyloxazole-4-carboxylate
• 英文别名: 5-Methyloxazol-4-carbonsaeure-methylester；methyl 5-methyl-1,3-oxazole-4-carboxylate
• CAS: 41172-57-0
• 化学式: C₆H₇NO₃
• mdl: MFCD08689502
• 分子量: 141.126
• InChiKey: UMYOVEXLUCPUAU-UHFFFAOYSA-N

物化性质

• 熔点：
  45-48
• 沸点：
  100 °C(Press: 7 Torr)
• 密度：
  1.179±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  52.3
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2934999090
• 储存条件：
  2-8°C，干燥密封保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 5-methyloxazole-4-carboxylate
Synonyms: Methyl 5-methyl-4-oxazolecarboxylate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 5-methyloxazole-4-carboxylate
CAS number: 41172-57-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H7NO3
Molecular weight: 141.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-甲基恶唑-4-甲酸甲酯 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 4.0h， 以82%的产率得到5-甲基-1,3-异恶唑-4-甲酸
  参考文献：
  名称：

  用于小沟 DNA 识别的可编程寡聚体

  摘要：

  DNA 的四个 Watson-Crick 碱基对可以通过并排配对三个五元芳香羧酰胺、咪唑 (Im)、吡咯 (Py) 和羟基吡咯 (Hp)，四种不同的方式在小沟中区分。基于用于小沟识别的芳环不对称配对边缘的范式，第二代杂环对，咪唑并吡啶/吡咯（Ip/Py）和羟基苯并咪唑/吡咯（Hz/Py），揭示了识别元件不是基于可以实现对远霉素类似物的研究。一组新的末端杂环二聚体，恶唑-羟基苯并咪唑 (No-Hz) 和氯噻吩-羟基苯并咪唑 (Ct-Hz)，与 Py-Py 配对显示结合小沟中 DNA 的连续碱基对，特别是 5' -GT-3' 和 5'-TT-3'，具有高亲和力和选择性。

  DOI：

  10.1021/ja0621795
• 作为产物：
  描述：

  2-Diazo-3-oxo-butyric acid methyl ester 在 dirhodium tetraacetate 碘 、 三乙胺 、 三苯基膦 作用下， 以 二氯甲烷 、 1,2-二氯乙烷 为溶剂， 反应 16.0h， 生成 5-甲基恶唑-4-甲酸甲酯
  参考文献：
  名称：

  N–H Insertion reactions of rhodium carbenoids. Part 5: A convenient route to 1,3-azoles

  摘要：

  Dirhodium(II) carboxylate catalysed reaction of diazocarbonyl compounds 2 in the presence of primary amides 1 results in the formation of alpha-acylaminoketones 3 (12 examples) by N-H insertion reaction of the intermediate rhodium carbene. The 1,4-dicarbonyl compounds 3 are readily converted into structurally diverse oxazoles 4 (11 examples) by cyclodehydration, thiazoles 5 (10 examples) by treatment with Lawesson's reagent, or imidazoles 6 (2 examples) by reaction with ammonia or methylamine. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2004.03.037

文献信息

• Syntheses of substituted-oxazolo-1,3,4-thiadiazoles, 1,3,4-oxadiazoles, and 1,2,4-triazoles
  作者：A. Shafiee、E. Naimi、P. Mansobi、A. Foroumadi、M. Shekari

  DOI：10.1002/jhet.5570320424

  日期：1995.7

  Starting from readily available methyl 5-methyloxazole-4-carboxylate (1) and 4-methyl-5-oxazolylcar-boxylic acid hydrazide (11) the title compounds were prepared. The reaction of compound 1 with hydrazine hydrate afforded the corresponding hydrazide 2. The reaction of compound 2 with formic acid yielded 1-formyl-2-(5-methyloxazole-4-carboxyl)hydrazine (3). Refluxing of the latter with phosphorus pentasulfide

  从容易获得的5-甲基恶唑-4-羧酸甲酯（1）和4-甲基-5-恶唑基-羧酰肼（11）开始，制备标题化合物。化合物1与水合肼的反应得到相应的酰肼2。化合物2与甲酸的反应产生1-甲酰基-2-（5-甲基恶唑-4-羧基）肼（3）。后者用五硫化二磷在二甲苯中回流，得到化合物5，产率为62％。化合物3与五氧化二磷反应，得到化合物4。从酰肼11开始，化合物13和14个类似地准备。化合物2与取代的异硫氰酸酯反应，得到化合物9，其在碱性介质中环化成4-烷基-5-（5-甲基-4-恶唑基）-2,4-二氢-3 H -1,2,4-三唑- 3-硫酮（10）。类似地制备异构体19。化合物19的甲基化和随后的氧化得到化合物21。在三氯氧磷存在下，酸7与硫代氨基脲反应，得到2-氨基-5-（5-甲基-4-恶唑基）1,3,4-噻二唑（8）。2-氨基-5-（4-甲基-5-恶唑基）-1,3,4-噻二唑（17通过常规方法由酰氯15制备）。
• 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
  申请人：——

  公开号：US20030109539A1

  公开（公告）日：2003-06-12

  The present invention is directed to novel 1,3,8-triazaspiro[4.5]decan-4-one derivatives of the general formula 1 wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, substance abuse, neuropathic pain, acute pain, migraine, asthma, cough and for improved cognition.

  本发明涉及一种新颖的一舁3，8-三氮杂螺[4.5]癸烷-4-酮衍生物，其一般式如下： 1 其中所有变量如本文所定义，在治疗由ORL-1 G蛋白偶联受体介导的疾病和症状中有用。更具体地，本发明的化合物在治疗焦虑、抑郁、物质滥用、神经病痛、急性疼痛、偏头痛、哮喘、咳嗽和改善认知方面有用。
• [EN] ALKYNYL ALCOHOLS AS KINASE INHIBITORS<br/>[FR] ALCOOLS D'ALCYNYLE UTILISÉS COMME INHIBITEURS DE KINASES
  申请人：AMGEN INC

  公开号：WO2009158011A1

  公开（公告）日：2009-12-30

  Selected compounds are effective for prophylaxis and treatment of inflammation and inflammatory disorders, such as NIK-mediated disorders. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, inflammation and the like.

  选定的化合物对预防和治疗炎症和炎症性疾病，如NIK介导的疾病，具有有效性。该发明涵盖了新颖的化合物、类似物、前药及其药用可接受的盐，以及用于预防和治疗涉及炎症等疾病和其他疾病或病症的药物组合物和方法。
• [EN] COMPOUNDS FOR THE TREATMENT OF HEPATITIS C<br/>[FR] COMPOSÉS UTILISABLES POUR LE TRAITEMENT DE L'HÉPATITE C
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011112191A1

  公开（公告）日：2011-09-15

  The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

  本公开提供了公式(I)的化合物，包括它们的盐，以及使用这些化合物的组合物和方法。这些化合物对丙型肝炎病毒(HCV)具有活性，可能对治疗HCV感染者有益。
• [EN] BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS<br/>[FR] INHIBITEURS DE LA DIHYDROOROTATE DÉSHYDROGÉNASE BI-ARYLE
  申请人：JANSSEN BIOTECH INC

  公开号：WO2021070132A1

  公开（公告）日：2021-04-15

  Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula I as follows: Formula I wherein R1, R2, R3, and Q are defined herein.

  披露了用于治疗受DHODH调制影响的疾病、失调或医疗条件的化合物、组合物和方法。这些化合物由以下式I表示：式I其中R1、R2、R3和Q在此定义。